ZNTL - Zentalis Operating profit EBITDA

Brandmark of Zentalis (ZNTL)

Zentalis Pharmaceuticals (ZNTL) is developing the innovative azazenisertib to combat resistant tumors. Flawless thermologistics of the drugs guarantee therapy effectiveness, as confirmed by historical data on the GURU.Markets chart: the base EBITDA level shows that the latest mark is 0.00. The issuer's future success is based on clinical test results, while the current cash reserve remains sufficient.

Zentalis Pharmaceuticals (ZNTL) - Operating profit EBITDA from 11/23/2025 to 11/17/2026

Summary analytical data breakdowns for Zentalis Pharmaceuticals Inc (ZNTL)

Fundamental company valuation:Zentalis Pharmaceuticals, ZNTL
Manufactured product of Zentalis Pharmaceuticals, Inc.

This indicator tracks daily net operating cash flow, allowing investors to promptly identify a critical reduction in resources for business development. When analyzing the EBITDA_Co trend, it should be noted that for Zentalis Pharmaceuticals (ZNTL), a lack of pricing power due to the clinical trial stage makes this metric a key marker of survival until regulatory certification of the drugs.